Related coverage linked through entity extraction aliases.
Feb 25, 2026
The U.S. recorded 2,280 measles cases in 2025, the highest since 1991, with 982 cases already confirmed in early 2026. North London faces an outbreak with 34 children infected in Enfield, while Philadelphia issued an exposure alert for the international airport.
Feb 19, 2026
Orca-T, an investigational T-cell therapy under FDA priority review, is being studied to reduce graft-versus-host disease in patients undergoing allogeneic stem cell transplant for acute leukemias and high-risk blood disorders, with a decision expected in April 2026.
Feb 23, 2026
Microdosing GLP-1 medications like Ozempic and Wegovy has emerged as a weight-loss trend, but health experts warn there is no scientific data supporting the practice and caution about potential safety risks.
Feb 23, 2026
The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.
Feb 20, 2026
The FDA has approved a supplemental new drug application for the combination regimen of Venclexta (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia, supported by Phase 3 AMPLIFY trial data.
Feb 20, 2026
The FDA approved AbbVie's combination of Venclexta and acalabrutinib as the first all-oral, fixed-duration treatment for previously untreated chronic lymphocytic leukemia patients, based on Phase 3 trial data showing 35% reduction in disease progression risk.
Feb 20, 2026
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration regimen for previously untreated chronic lymphocytic leukemia, based on phase III AMPLIFY trial results showing 35% reduction in disease progression or death risk versus chemoimmunotherapy.
Feb 18, 2026
GLP-1 weight loss drugs show increasing efficacy but raise concerns about excessive weight loss, side effects, and the rise of unregulated compounded versions sold online.
Feb 19, 2026
Pivya (pivmecillinam) is now available in the US for treating uncomplicated urinary tract infections in adult female patients, based on three phase 3 trials showing efficacy against susceptible bacterial isolates.
Feb 20, 2026
The FDA has approved the combination of Venclexta (venetoclax) plus acalabrutinib as the first all-oral, fixed-duration regimen for previously untreated adults with chronic lymphocytic leukemia, based on Phase III AMPLIFY study results.
Feb 18, 2026
The FDA has expanded a recall of raw oysters from Stellar Bay Shellfish due to norovirus contamination and issued a nationwide recall of Tippy Toes baby food fruit puree due to elevated patulin levels.
Feb 14, 2026
Clinical studies demonstrate GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss when combined with lifestyle changes, with patients achieving mean reductions of 14.9% body weight over 68 weeks.
Feb 13, 2026
CDC and FDA are investigating a multistate outbreak of extensively drug-resistant Salmonella Newport infections linked to Rosabella brand moringa powder capsules, with seven people sickened across seven states and three requiring hospitalization.
Oct 01, 2025
The FDA approved Zycubo (copper histidinate) on January 13, 2026, as the first treatment for Menkes disease in pediatric patients, following resolution of manufacturing compliance concerns that led to an initial rejection in September 2025.
Jan 16, 2026
The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen, for cancer patients at risk of infection due to chemotherapy and other indications. The approval marks Accord BioPharma's sixth biosimilar product.
Feb 12, 2026
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
Feb 13, 2026
The FDA announced plans to restrict non-FDA-approved compounded GLP-1 drugs mass-marketed as alternatives to approved weight loss medications, citing safety concerns and misleading advertising practices.
